Results 81 to 90 of about 35,905 (251)

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Ultrasmall Fe‐curcumin immunomodulators reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence

BMEMat, EarlyView.
This work discovered a novel research that ultrasmall Fe‐curcumin immunomodulators could reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence. Abstract CAR‐T cell immunotherapy has achieved exciting success in hematologic malignancies, but the therapeutic efficacy is relatively limited in solid ...
Jiazhi Duan, Yuchan Xue, Miao Zhang, Zihao Zhang, Shiyu Peng, Minghao Sui, Han Ding, Yingying Nie, Yuemin Feng, Le Wang, Tianru Zhang, Mingchuan Yu, He Xia, Hong Liu, Qiang Zhu, Songbo Zhao   +15 more
wiley   +1 more source

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

Oncoimmunology, 2016
We report here the successful vectorization of a hamster monoclonal IgG (namely J43) recognizing the murine Programmed cell death-1 (mPD-1) in Western Reserve (WR) oncolytic vaccinia virus.
P. Kleinpeter, Laetitia Fend, C. Thioudellet, M. Geist, Nathalie Sfrontato, Véronique Koerper, Catherine Fahrner, D. Schmitt, M. Gantzer, Christelle Remy-Ziller, R. Brandely, D. Villeval, K. Rittner, N. Silvestre, P. Erbs, L. Zitvogel, E. Quéméneur, X. Preville, Jean-Baptiste Marchand   +18 more
semanticscholar   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Novel single-chain fragment variable antibody targeting plasma membrane epitopes on porcine Y-chromosome-bearing sperm

Scientific Reports
The aim of this study was to construct and produce a single-chain fragment variable (scFv) antibody targeting the plasma membrane epitope on porcine Y-chromosome-bearing sperm (Y-sperm). The hybridoma cloned from 4D1-E8 exhibited the highest specificity,
Marninphan Thongkham, Surat Hongsibsong, Supamit Mekchay, Anucha Sathanawongs, Xue-Ming Cao, Zhen-Lin Xu, Korawan Sringarm   +6 more
doaj   +1 more source

Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp

Frontiers in Cellular and Infection Microbiology, 2013
Single-chain variable fragment (scFv) is a class of engineered antibodies generated by the fusion of the heavy (VH) and light chains (VL) of immunoglobulins through a short polypeptide linker.
Rongzhi eWang, Shuangshuang eXiang, Youjun eFeng, Swaminath eSrinivas, Yonghui eZhang, Mingshen eLin, Shihua eWang   +6 more
doaj   +1 more source

Screening of bispecific antibodies during single cell cloning of recombinant Chinese hamster ovary cell lines to improve titer and product quality

Biotechnology Progress, EarlyView.
Abstract Development of therapeutic bispecific antibodies (BsAbs) poses significant manufacturability challenges associated with correct chain pairing and an increased diversity of impurities. Here we address this with a product quality assessment during cell line development (CLD), forgoing the need for genetic characterization during cell line ...
Molly Robinson, Jessica Willmott, Holly Corrigall, Daniela Lega, Joseph Stirling, Vithiya Vimalraj, Mitul Patel, Robyn Emmins   +7 more
wiley   +1 more source

Recombinant Monoclonal Antibodies for Detecting the Tubulin Post‐Translational Modifications Glutamylation and Lysine‐40 Acetylation

Cytoskeleton, EarlyView.
ABSTRACT Post‐translational modifications (PTMs) to tubulin subunits in microtubule filaments are thought to comprise a component of the tubulin code that specifies microtubule functions in cell physiology and animal development. Acetylation of Lysine‐40 (K40) on α‐tubulin (αTub‐K40ac) and glutamylation of both α‐ and β‐tubulin are two tubulin PTMs of ...
Lynne Blasius, Ezekiel C. Thomas, Erik H. Collet, Erin Jenson, Chad G. Pearson, Ryoma Ohi, Kristen J. Verhey   +6 more
wiley   +1 more source

Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy

Cellular and Molecular Life Sciences, 2021
Yanting Duan, Ruoqi Chen, Yanjie Huang, Xianhui Meng, Jiangqing Chen, C. Liao, Yongmin Tang, Chun Zhou, Xiaofei Gao, Jie Sun   +9 more
semanticscholar   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source